GSK 2321138A

Drug Profile

GSK 2321138A

Alternative Names: FLU D-QIV; Fluarix Quadrivalent; Fluarix Tetra; Fluarix Tetra 2013/2014; GSK-2321138A; Influsplit Tetra; Influsplit Tetra 2013/2014; Quadrivalent influenza vaccine – GlaxoSmithKline

Latest Information Update: 03 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 26 Oct 2016 Immunogenicity and adverse events data from a phase III trial in Influenza presented at IDWeek 2016 (IDW-2016)
  • 02 Jun 2015 No recent reports of development identified - Phase-III for Influenza virus infections (Prevention) in Romania (IM)
  • 01 Jun 2015 GlaxoSmithKline completes a Phase III trial for Influenza virus infections (Prevention, In adults, In the elderly) in Brazil (NCT02369341)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top